Drug Discovery 기술 시장(2026-2030년)

The global drug discovery technology market is forecasted to grow by USD 31567.4 mn during 2025-2030, accelerating at a CAGR of 9.1% during the forecast period. The report on the global drug discovery technology market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing demand for precision medicine research and targeted therapeutics, expansion of strategic collaborations across pharmaceutical and biotechnology ecosystem, increasing adoption of digital biology and computational discovery platforms.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global drug discovery technology market is segmented as below:

By Product

• Genomics
• Proteomics
• Bioinformatics
• HTS
• Others

By End-User

• Pharmaceutical and biotechnology companies
• Academic and research institutes
• CROs

By Therapeutic Area

• Oncology
• Neurology
• CVD
• Infectious diseases
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the shift toward multimodal biological data integration as one of the prime reasons driving the global drug discovery technology market growth during the next few years. Also, expansion of externalized discovery ecosystems and platform based research models and increasing use of real world and longitudinal data in discovery workflows will lead to sizable demand in the market.

The report on the global drug discovery technology market covers the following areas:

• Global drug discovery technology market sizing
• Global drug discovery technology market forecast
• Global drug discovery technology market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global drug discovery technology market vendors that include Agilent Technologies Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc., BioMerieux SA, Bruker Corp., Carl Zeiss AG, Charles River Laboratories, Corning Inc., Danaher Corp., Eppendorf SE, Eurofins Scientific SE, F. Hoffmann La Roche Ltd., GenScript Biotech Corp., Illumina Inc., Lonza Group Ltd., Merck KGaA, Promega Corp., QIAGEN N.V., Revvity Inc., Sartorius AG, Shimadzu Corp., Takara Bio Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., Waters Corp.. Also, the global drug discovery technology market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Product
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Therapeutic Area
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Drug Discovery Technology Market 2020 - 2024
  • Historic Market Size - Data Table on Global Drug Discovery Technology Market 2020 - 2024 ($ million)
• 5.2 Product segment analysis 2020 - 2024
  • Historic Market Size - Product Segment 2020 - 2024 ($ million)
• 5.3 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.4 Therapeutic Area segment analysis 2020 - 2024
  • Historic Market Size - Therapeutic Area Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global drug discovery technology market
• 6.2 Impact of geopolitical conflicts on global drug discovery technology market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Product

• 8.1 Market segments
• 8.2 Comparison by Product
• 8.3 Genomics - Market size and forecast 2025-2030
• 8.4 Proteomics - Market size and forecast 2025-2030
• 8.5 Bioinformatics - Market size and forecast 2025-2030
• 8.6 HTS - Market size and forecast 2025-2030
• 8.7 Others - Market size and forecast 2025-2030
• 8.8 Market opportunity by Product
  • Market opportunity by Product ($ million)

9 Market Segmentation by End-user

• 9.1 Market segments
• 9.2 Comparison by End-user
• 9.3 Pharmaceutical and biotechnology companies - Market size and forecast 2025-2030
• 9.4 Academic and research institutes - Market size and forecast 2025-2030
• 9.5 CROs - Market size and forecast 2025-2030
• 9.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

10 Market Segmentation by Therapeutic Area

• 10.1 Market segments
• 10.2 Comparison by Therapeutic Area
• 10.3 Oncology - Market size and forecast 2025-2030
• 10.4 Neurology - Market size and forecast 2025-2030
• 10.5 CVD - Market size and forecast 2025-2030
• 10.6 Infectious diseases - Market size and forecast 2025-2030
• 10.7 Others - Market size and forecast 2025-2030
• 10.8 Market opportunity by Therapeutic Area
  • Market opportunity by Therapeutic Area ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 India - Market size and forecast 2025-2030
  • 12.5.3 Japan - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Australia - Market size and forecast 2025-2030
  • 12.6.3 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.4 UAE - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Growing demand for precision medicine research and targeted therapeutics
  • Expansion of strategic collaborations across pharmaceutical and biotechnology ecosystem
  • Increasing adoption of digital biology and computational discovery platforms
• 13.2 Market challenges
  • High research failure rates and limited clinical translation
  • Rising technology implementation and infrastructure costs
  • Data integration complexity and regulatory compliance burden
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Shift toward multimodal biological data integration
  • Expansion of externalized discovery ecosystems and platform based research models
  • Increasing use of real world and longitudinal data in discovery workflows

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Becton Dickinson and Co.
  • Becton Dickinson and Co. - Overview
  • Becton Dickinson and Co. - Business segments
  • Becton Dickinson and Co. - Key news
  • Becton Dickinson and Co. - Key offerings
  • Becton Dickinson and Co. - Segment focus
  • SWOT
• 15.5 Carl Zeiss AG
  • Carl Zeiss AG - Overview
  • Carl Zeiss AG - Product / Service
  • Carl Zeiss AG - Key offerings
  • SWOT
• 15.6 Corning Inc.
  • Corning Inc. - Overview
  • Corning Inc. - Business segments
  • Corning Inc. - Key offerings
  • Corning Inc. - Segment focus
  • SWOT
• 15.7 Danaher Corp.
  • Danaher Corp. - Overview
  • Danaher Corp. - Business segments
  • Danaher Corp. - Key news
  • Danaher Corp. - Key offerings
  • Danaher Corp. - Segment focus
  • SWOT
• 15.8 Eppendorf SE
  • Eppendorf SE - Overview
  • Eppendorf SE - Product / Service
  • Eppendorf SE - Key offerings
  • SWOT
• 15.9 Eurofins Scientific SE
  • Eurofins Scientific SE - Overview
  • Eurofins Scientific SE - Business segments
  • Eurofins Scientific SE - Key offerings
  • Eurofins Scientific SE - Segment focus
  • SWOT
• 15.10 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.11 GenScript Biotech Corp.
  • GenScript Biotech Corp. - Overview
  • GenScript Biotech Corp. - Business segments
  • GenScript Biotech Corp. - Key offerings
  • GenScript Biotech Corp. - Segment focus
  • SWOT
• 15.12 Illumina Inc.
  • Illumina Inc. - Overview
  • Illumina Inc. - Business segments
  • Illumina Inc. - Key news
  • Illumina Inc. - Key offerings
  • Illumina Inc. - Segment focus
  • SWOT
• 15.13 Lonza Group Ltd.
  • Lonza Group Ltd. - Overview
  • Lonza Group Ltd. - Business segments
  • Lonza Group Ltd. - Key news
  • Lonza Group Ltd. - Key offerings
  • Lonza Group Ltd. - Segment focus
  • SWOT
• 15.14 Merck KGaA
  • Merck KGaA - Overview
  • Merck KGaA - Business segments
  • Merck KGaA - Key news
  • Merck KGaA - Key offerings
  • Merck KGaA - Segment focus
  • SWOT
• 15.15 Revvity Inc.
  • Revvity Inc. - Overview
  • Revvity Inc. - Business segments
  • Revvity Inc. - Key offerings
  • Revvity Inc. - Segment focus
  • SWOT
• 15.16 Sartorius AG
  • Sartorius AG - Overview
  • Sartorius AG - Business segments
  • Sartorius AG - Key offerings
  • Sartorius AG - Segment focus
  • SWOT
• 15.17 Shimadzu Corp.
  • Shimadzu Corp. - Overview
  • Shimadzu Corp. - Business segments
  • Shimadzu Corp. - Key offerings
  • Shimadzu Corp. - Segment focus
  • SWOT
• 15.18 Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc. - Overview
  • Thermo Fisher Scientific Inc. - Business segments
  • Thermo Fisher Scientific Inc. - Key news
  • Thermo Fisher Scientific Inc. - Key offerings
  • Thermo Fisher Scientific Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations